Two patients were treated for hepatocellular carcinoma and one patient was treated for malignant colorectal cancer metastasised to the liver.
DC Bead Lumi is the first commercially available radiopaque drug-eluting bead in the EU which can be loaded with doxorubicin or irinotecan for the local treatment of tumours in patients with hepatocellular carcinoma and metastatic colorectal cancer, respectively. DC Bead Lumi is a next-generation development of DC Bead.
At the Istituto Oncologico Veneto, Padova, Italy, Camillo Aliberti, director of Radiology, and his team performed transarterial chemoembolization (TACE) procedures using DC Bead Lumi, enabling real-time, visible, lasting confirmation of bead location during and after embolization of tumours in the liver.
“We are very pleased with the results from treatment in our patients, and DC Bead Lumi offered clear, real-time evidence on the treatment of the target lesion while the long-term radiopacity means not only can we see where we are delivering the treatment during the procedure, but we can also identify areas of successful treatment—or under treatment—in follow-up scans,”Aliberti said.
“DC Bead Lumi provides the opportunity to individualise a patient’s treatment and bring a new level of control to TACE procedures. At the same time, the lasting radiopacity allows you to see rather than assume the location of the beads, providing reassurance to patients that the treatment is getting to where it needs to be,” commented Duncan Kennedy, BTG head of Interventional Oncology.
DC Bead Lumi gained class III CE mark certification in early March, 2017.
